Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Has $16.83 Million Position in Amgen Inc. $AMGN

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA cut its position in shares of Amgen Inc. (NASDAQ:AMGN) by 4.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 57,459 shares of the medical research company’s stock after selling 2,464 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Amgen were worth $16,829,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the company. Marquette Asset Management LLC raised its stake in Amgen by 22.6% in the third quarter. Marquette Asset Management LLC now owns 315 shares of the medical research company’s stock valued at $89,000 after buying an additional 58 shares during the period. Tema Etfs LLC boosted its stake in shares of Amgen by 38.4% during the 3rd quarter. Tema Etfs LLC now owns 17,964 shares of the medical research company’s stock worth $5,069,000 after acquiring an additional 4,987 shares during the period. Aspiriant LLC increased its holdings in shares of Amgen by 1.5% during the 3rd quarter. Aspiriant LLC now owns 4,475 shares of the medical research company’s stock worth $1,263,000 after acquiring an additional 64 shares during the last quarter. Washington Trust Bank raised its stake in Amgen by 9.6% in the 3rd quarter. Washington Trust Bank now owns 2,046 shares of the medical research company’s stock valued at $577,000 after acquiring an additional 179 shares during the period. Finally, Bayforest Capital Ltd lifted its holdings in Amgen by 1,034.8% during the 3rd quarter. Bayforest Capital Ltd now owns 261 shares of the medical research company’s stock valued at $74,000 after purchasing an additional 238 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Bank of America upped their price objective on shares of Amgen from $261.00 to $272.00 and gave the company an “underperform” rating in a report on Friday, September 26th. Scotiabank began coverage on shares of Amgen in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $385.00 price target on the stock. Guggenheim increased their price target on shares of Amgen from $288.00 to $305.00 and gave the company a “neutral” rating in a report on Thursday, November 6th. Deutsche Bank Aktiengesellschaft boosted their price objective on Amgen from $280.00 to $285.00 and gave the stock a “hold” rating in a report on Tuesday, November 11th. Finally, Morgan Stanley lowered their target price on Amgen from $329.00 to $304.00 and set an “equal weight” rating on the stock in a research note on Friday, December 12th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Amgen presently has a consensus rating of “Moderate Buy” and an average price target of $338.55.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: UBS upgraded Amgen (AMGN) to a “strong-buy,” a direct bullish analyst signal that can support the stock. UBS upgrade: Amgen to strong-buy
• Positive Sentiment: Amgen struck an exclusive deal with Disco/Disco Pharma tied to a cancer target (deal worth up to $618M), which strengthens Amgen’s oncology pipeline and future revenue optionality. Amgen Disco oncology pact
• Positive Sentiment: Amgen completed a Phase 1b blinatumomab study in Japan, advancing its leukemia strategy — a clinical progress update that can de-risk a program and support long-term value. Blinatumomab study completed in Japan
• Neutral Sentiment: Truist nudged Amgen’s price target slightly higher (from $318 to $319) but kept a “hold” rating — a mild signal that doesn’t materially change sell-side sentiment. Truist raises AMGN price target to $319
• Neutral Sentiment: Citi reiterated a “hold” on Amgen, indicating continued analyst caution despite pipeline wins. Citi sticks to hold for Amgen
• Neutral Sentiment: Market/sector context: Amgen is tracking with the Nasdaq life-sciences segment and will be in focus at the JPMorgan Healthcare Conference, where peers typically reveal pipeline updates and M&A intent — a neutral-to-positive thematic tailwind depending on conference takeaways. AMGN aligns with Nasdaq life sciences
• Neutral Sentiment: Sector preview: CNBC notes JPMorgan Healthcare will drive pipeline/M&A headlines across big pharmas — Amgen may benefit if it announces high-impact deals. What to expect from pharma at JPM
• Negative Sentiment: Despite the positive deal and clinical updates, shares fell amid a broader market uptick and profit-taking; a Zacks note highlighted recent intraday weakness, reflecting short-term selling pressure. Amgen stock falls amid market uptick

Amgen Trading Down 1.2%

NASDAQ AMGN opened at $326.10 on Monday. The business has a 50 day moving average price of $329.75 and a 200-day moving average price of $304.66. The company has a market cap of $175.60 billion, a price-to-earnings ratio of 25.20, a P/E/G ratio of 2.97 and a beta of 0.45. The company has a quick ratio of 0.99, a current ratio of 1.28 and a debt-to-equity ratio of 5.45. Amgen Inc. has a 52 week low of $260.55 and a 52 week high of $346.38.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.01 by $0.63. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The company had revenue of $9.56 billion during the quarter, compared to analyst estimates of $8.98 billion. During the same period in the prior year, the company posted $5.58 earnings per share. Amgen’s quarterly revenue was up 12.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. As a group, equities analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be given a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 3.1%. This is a positive change from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date is Friday, February 13th. Amgen’s dividend payout ratio (DPR) is currently 73.57%.

Insiders Place Their Bets

In related news, SVP Rachna Khosla sold 890 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total transaction of $299,253.60. Following the completion of the sale, the senior vice president owned 7,082 shares of the company’s stock, valued at $2,381,251.68. This trade represents a 11.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Murdo Gordon sold 6,879 shares of Amgen stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total value of $2,317,053.57. Following the completion of the sale, the executive vice president directly owned 41,923 shares of the company’s stock, valued at approximately $14,120,924.09. The trade was a 14.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 10,908 shares of company stock valued at $3,674,966 over the last 90 days. Insiders own 0.69% of the company’s stock.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.